Suppr超能文献

经导管动脉化治疗慢性肢体威胁性缺血的深静脉:与保肢相关的直接成本病例系列

Transcatheter Arterialization of the Deep Veins for Chronic Limb-Threatening Ischemia: A Case Series of the Direct Cost Associated With Limb Salvage.

作者信息

Malkoc Aldin, Miao Xinfei, Mamoun Lana, Lai Catherine, GnanaDev Raja, Lee Michelle, Lee Samuel, Schwartz Samuel

机构信息

Department of Surgery, Arrowhead Regional Medical Center, Colton, CA 92324, USA.

California University of Science and Medicine, Colton, CA 92324, USA.

出版信息

J Med Cases. 2025 Aug 22;16(8):318-322. doi: 10.14740/jmc5155. eCollection 2025 Aug.

Abstract

Our study aims to estimate the long-term cost of procedurally successful transcatheter arterialization of the deep veins (TADV) coupled with adjunct therapy. Patients with no conventional endovascular/open options were considered for TADV. TADV index procedure cost, cost of subsequent procedures and wound care/adjuncts were collected. Cost data were obtained from Medicare claims and other published sources. All patients in the study had limb salvage 180 days after TADV. Success was defined as lime salvage with no more than a transmetatarsal amputation of the affected limb. The average cost of the procedure was $320,850. The average hospital cost (hospitalization and wound care adjuncts) was $895,546. The overall average total cost was $1,216,396. TADV and associated multidisciplinary wound care approach for "no option" chronic limb-threatening ischemia does not appear to be a cost-effective strategy, with an average total cost of over 1 million dollars per patient.

摘要

我们的研究旨在评估成功进行深静脉导管动脉化(TADV)并辅以辅助治疗的长期成本。对于没有传统血管内/开放手术选择的患者,考虑进行TADV。收集了TADV首次手术成本、后续手术成本以及伤口护理/辅助治疗的成本。成本数据来自医疗保险索赔和其他已发表的来源。研究中的所有患者在TADV术后180天均保住了肢体。成功的定义为保住肢体,且受影响肢体的截肢不超过经跖骨截肢。该手术的平均成本为320,850美元。平均住院成本(住院和伤口护理辅助治疗)为895,546美元。总体平均总成本为1,216,396美元。对于“无选择”的慢性肢体威胁性缺血,TADV及相关的多学科伤口护理方法似乎不是一种具有成本效益的策略,每位患者的平均总成本超过100万美元。

相似文献

2
Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemia.
N Engl J Med. 2023 Mar 30;388(13):1171-1180. doi: 10.1056/NEJMoa2212754.
3
Outcomes following deep venous arterialization in Medicare patients with chronic limb-threatening ischemia.
J Vasc Surg. 2025 Sep;82(3):1007-1013. doi: 10.1016/j.jvs.2025.04.003. Epub 2025 Apr 11.
4
1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies.
JACC Cardiovasc Interv. 2025 Jul 14;18(13):1675-1685. doi: 10.1016/j.jcin.2025.05.004.
6
Textbook outcomes after revascularization for chronic limb-threatening ischemia remain rare.
J Vasc Surg. 2025 Aug;82(2):536-548.e5. doi: 10.1016/j.jvs.2025.03.202. Epub 2025 Apr 2.

本文引用的文献

1
Efficacy and Durability of Percutaneous Deep Vein Arterialization: A Systematic Review.
Ann Vasc Surg. 2024 Aug;105:89-98. doi: 10.1016/j.avsg.2024.01.008. Epub 2024 Apr 3.
2
Outcomes and Patency of Endovascular Infrapopliteal Reinterventions in Patients With Chronic Limb-Threatening Ischemia.
J Endovasc Ther. 2024 Oct;31(5):831-839. doi: 10.1177/15266028221147457. Epub 2023 Jan 7.
3
Management of the no-option foot: Deep vein arterialization.
Semin Vasc Surg. 2022 Jun;35(2):210-218. doi: 10.1053/j.semvascsurg.2022.05.002. Epub 2022 May 25.
5
Deep Venous Arterialization for Chronic Limb Threatening Ischemia in Atherosclerosis Patients - A Meta-Analysis.
Ann Vasc Surg. 2022 Apr;81:1-21. doi: 10.1016/j.avsg.2021.10.059. Epub 2021 Dec 7.
6
Advances in chronic limb-threatening ischemia.
Vasc Med. 2021 Apr;26(2):126-130. doi: 10.1177/1358863X21998436.
7
The Role of Lower Extremity Amputation in Chronic Limb-Threatening Ischemia.
Int J Angiol. 2020 Sep;29(3):149-155. doi: 10.1055/s-0040-1710075. Epub 2020 May 14.
9
Open, percutaneous, and hybrid deep venous arterialization technique for no-option foot salvage.
J Vasc Surg. 2020 Jun;71(6):2152-2160. doi: 10.1016/j.jvs.2019.10.085. Epub 2019 Dec 31.
10
The burden of critical limb ischemia: a review of recent literature.
Vasc Health Risk Manag. 2019 Jul 1;15:187-208. doi: 10.2147/VHRM.S209241. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验